EA015709B1 - Педиатрический аминокислотный раствор для парентерального питания и его применение - Google Patents
Педиатрический аминокислотный раствор для парентерального питания и его применение Download PDFInfo
- Publication number
- EA015709B1 EA015709B1 EA200870451A EA200870451A EA015709B1 EA 015709 B1 EA015709 B1 EA 015709B1 EA 200870451 A EA200870451 A EA 200870451A EA 200870451 A EA200870451 A EA 200870451A EA 015709 B1 EA015709 B1 EA 015709B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- amino acid
- acid solution
- amino acids
- solution according
- tyrosine
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 title claims abstract description 125
- 235000016236 parenteral nutrition Nutrition 0.000 title claims abstract description 28
- 235000001014 amino acid Nutrition 0.000 claims abstract description 107
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 33
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 32
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 28
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 28
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 16
- 108010038807 Oligopeptides Proteins 0.000 claims abstract description 16
- 102000015636 Oligopeptides Human genes 0.000 claims abstract description 16
- 235000018417 cysteine Nutrition 0.000 claims abstract description 16
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 16
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229960003080 taurine Drugs 0.000 claims abstract description 16
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 9
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims abstract description 9
- 229930182817 methionine Natural products 0.000 claims abstract description 9
- 229940024606 amino acid Drugs 0.000 claims description 105
- 239000000243 solution Substances 0.000 claims description 59
- 239000000203 mixture Substances 0.000 claims description 26
- 230000001954 sterilising effect Effects 0.000 claims description 18
- 238000004659 sterilization and disinfection Methods 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 230000037396 body weight Effects 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 11
- 239000003925 fat Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- 239000003792 electrolyte Substances 0.000 claims description 5
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- 239000003978 infusion fluid Substances 0.000 claims description 4
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- 239000011573 trace mineral Substances 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 108010044940 alanylglutamine Proteins 0.000 claims description 2
- 229960002648 alanylglutamine Drugs 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000017169 kidney disease Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- ALZVPLKYDKJKQU-XVKPBYJWSA-N Ala-Tyr Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 ALZVPLKYDKJKQU-XVKPBYJWSA-N 0.000 claims 1
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 claims 1
- XBGGUPMXALFZOT-VIFPVBQESA-N Gly-Tyr Chemical compound NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-VIFPVBQESA-N 0.000 claims 1
- 108010070783 alanyltyrosine Proteins 0.000 claims 1
- 229960002989 glutamic acid Drugs 0.000 claims 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 claims 1
- 108010010147 glycylglutamine Proteins 0.000 claims 1
- 108010087823 glycyltyrosine Proteins 0.000 claims 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 8
- 230000002028 premature Effects 0.000 description 17
- 230000004060 metabolic process Effects 0.000 description 10
- 239000002243 precursor Substances 0.000 description 9
- 108010016626 Dipeptides Proteins 0.000 description 7
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 7
- 235000013922 glutamic acid Nutrition 0.000 description 7
- 239000004220 glutamic acid Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CAHKINHBCWCHCF-UHFFFAOYSA-N N-acetyltyrosine Chemical compound CC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- -1 aromatic amino acids Chemical class 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 150000004667 medium chain fatty acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102000020018 Cystathionine gamma-Lyase Human genes 0.000 description 1
- 108010045283 Cystathionine gamma-lyase Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010017877 Gastrointestinal fistula Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108010069013 Phenylalanine Hydroxylase Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- DVXKFFRWCGVOGL-UHFFFAOYSA-N [Fe][Zn][Se] Chemical compound [Fe][Zn][Se] DVXKFFRWCGVOGL-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 239000002960 lipid emulsion Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007257 malfunction Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000004066 metabolic change Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000011903 nutritional therapy Methods 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 108010058198 sulfoalanine decarboxylase Proteins 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102006018293A DE102006018293A1 (de) | 2006-04-20 | 2006-04-20 | Pädiatrische Aminosäurelösung zur parenteralen Ernäherung |
| PCT/EP2007/001878 WO2007121807A1 (de) | 2006-04-20 | 2007-03-05 | Paediatrische aminosäurelösung zur parenteralen ernährung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200870451A1 EA200870451A1 (ru) | 2009-04-28 |
| EA015709B1 true EA015709B1 (ru) | 2011-10-31 |
Family
ID=38006821
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200870451A EA015709B1 (ru) | 2006-04-20 | 2007-03-05 | Педиатрический аминокислотный раствор для парентерального питания и его применение |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8377876B2 (enExample) |
| EP (1) | EP2007348B1 (enExample) |
| JP (1) | JP2009534323A (enExample) |
| KR (1) | KR20090010050A (enExample) |
| CN (2) | CN101420933A (enExample) |
| AR (1) | AR060555A1 (enExample) |
| AU (1) | AU2007241469B2 (enExample) |
| BR (1) | BRPI0710298A2 (enExample) |
| CA (1) | CA2647087A1 (enExample) |
| DE (1) | DE102006018293A1 (enExample) |
| EA (1) | EA015709B1 (enExample) |
| MX (1) | MX2008013540A (enExample) |
| TW (1) | TWI429405B (enExample) |
| WO (1) | WO2007121807A1 (enExample) |
| ZA (1) | ZA200807860B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2608232C2 (ru) * | 2012-01-09 | 2017-01-17 | Н.В. Нютрисиа | Обогащенная глутамином питательная композиция для недоношенных детей |
| RU2619294C2 (ru) * | 2013-01-09 | 2017-05-15 | Н.В. Нютрисиа | Улучшение познавательных способностей недоношенных детей, имеющих низкую массу для своего гестационного возраста |
| WO2020222671A1 (ru) * | 2019-04-29 | 2020-11-05 | Алексей Владимирович ВОРОНОВ | Солевой электролитный раствор для проведения энтеральных инфузий |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102065698A (zh) | 2008-06-19 | 2011-05-18 | 荷兰联合利华有限公司 | 具有铁和锌的含脂肪食用乳液 |
| AU2009268742C1 (en) | 2008-07-07 | 2013-11-28 | Pentec Health, Inc. | Nutritive compositions and methods of using same |
| JP2011121889A (ja) * | 2009-12-09 | 2011-06-23 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用アミノ酸組成物 |
| CA2786375A1 (en) * | 2010-01-04 | 2011-07-07 | Pentec Health, Inc. | Nutritive compositions and methods of using same |
| JP2011144116A (ja) * | 2010-01-12 | 2011-07-28 | En Otsuka Pharmaceutical Co Ltd | 炎症性腸疾患用添加剤 |
| US20110208153A1 (en) * | 2010-02-24 | 2011-08-25 | John Alvey | Formulations and methods for nutrient delivery |
| JP6000253B2 (ja) | 2010-09-24 | 2016-09-28 | ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド | 胃腸機能を改善するための材料および方法 |
| EP2489408A1 (de) * | 2011-01-13 | 2012-08-22 | Michael Tchirikov | Aminosäurezusammensetzung und deren Verwendung zur Behandlung von fetaler Wachstumsrestriktion (IUGR) und zur parenteralen Ernährung von extrem Frühgeborenen |
| MX368543B (es) * | 2012-02-08 | 2019-10-07 | Univ Florida | Composiciones para tratar diarrea inducida por rotavirus. |
| WO2014164736A1 (en) | 2013-03-11 | 2014-10-09 | University Of Florida Research Foundation, Incorporated | Materials and methods for improving lung function and for prevention and/or treatment of radiation-induced lung complications |
| CN103404934B (zh) * | 2013-08-24 | 2015-07-01 | 江苏阜丰生物科技有限公司 | 一种含谷氨酰胺的解酒固体饮料及其制备方法 |
| WO2015178762A1 (en) * | 2014-05-19 | 2015-11-26 | N.V. Nutricia | Enteral formulations for preterm infants comprising optimised phenylalanine intake levels |
| WO2015178761A1 (en) | 2014-05-19 | 2015-11-26 | N.V. Nutricia | Formulas comprising optimised amino acid profiles |
| JOP20190276A1 (ar) * | 2017-05-31 | 2019-11-27 | Napo Pharmaceuticals Inc | طرق وتركيبات لعلاج إسهال الحمض الصفراوي، والإسهال المرتبط باستئصال الأمعاء الدقيقة أو إزالة المرارة، ومتلازمة الأمعاء القصيرة |
| CN107898808B (zh) * | 2017-10-31 | 2021-04-27 | 华仁药业股份有限公司 | 小儿用静脉营养制剂 |
| EP4125436A4 (en) * | 2020-04-01 | 2024-05-15 | The E. Wolfson Medical Center | ULCEROUS COLITIS DIET, RELATED FORMULAS, PRODUCTS AND METHODS |
| US20220378077A1 (en) * | 2021-05-25 | 2022-12-01 | Baxter International Inc. | Ready-To-Use Parenteral Nutrition Formulation |
| IT202200015885A1 (it) * | 2022-07-27 | 2024-01-27 | St G Gaslini | Sacca standardizzata per alimentazione di nati pretermine e dispositivo di alimentazione di nati pretermine |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0087750A2 (de) * | 1982-02-25 | 1983-09-07 | Kabi Pharmacia GmbH | Glutaminhaltige Aminosäure-Zubereitungen |
| WO1991016067A1 (en) * | 1990-04-23 | 1991-10-31 | Research Corporation Technologies, Inc. | Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition |
| WO1992009277A1 (en) * | 1990-12-03 | 1992-06-11 | Kabi Pharmacia Ab | Nutrient supply |
| US5432160A (en) * | 1993-01-29 | 1995-07-11 | Kyowa Hakko Kohyo Co., Ltd. | Nutrient composition |
| US5561111A (en) * | 1994-12-23 | 1996-10-01 | The University Of Virginia Patent Foundation | Stable glutamine derivatives for oral and intravenous rehydration and nutrition therapy |
| WO2005030242A1 (en) * | 2003-09-26 | 2005-04-07 | University Of Florida Research Foundation, Inc | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2556594B1 (fr) * | 1983-12-20 | 1988-09-09 | Synthelabo | Solutions d'acides amines |
| US5684045A (en) * | 1985-09-12 | 1997-11-04 | Brigham And Women's Hospital | Method of treating pancreatic atrophy |
| JPH0710770A (ja) * | 1990-03-14 | 1995-01-13 | Otsuka Pharmaceut Factory Inc | アミノ酸輸液 |
| US5206220A (en) * | 1990-04-23 | 1993-04-27 | Research Corporation Technologies, Inc. | Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition |
| US5438042B1 (en) * | 1993-10-08 | 1997-08-26 | Sandoz Nutrition Ltd | Enteral nutritional composition having amino acid profile |
| FR2711529B1 (fr) * | 1993-10-28 | 1996-07-05 | Clintec Nutrition Cy | Composition à base d'acides aminés destinée au traitement d'une infection ou d'une agression engendrant une réaction inflammatoire, chez les animaux et chez l'homme. |
| US5719133A (en) * | 1994-09-21 | 1998-02-17 | Novartis Nutrition Ag | Adolescent dietary composition |
| US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
| ID27818A (id) * | 1998-03-31 | 2001-04-26 | Nestle Sa | Metode untuk menyediakan glutamin |
-
2006
- 2006-04-20 DE DE102006018293A patent/DE102006018293A1/de not_active Ceased
-
2007
- 2007-03-05 WO PCT/EP2007/001878 patent/WO2007121807A1/de not_active Ceased
- 2007-03-05 AU AU2007241469A patent/AU2007241469B2/en not_active Ceased
- 2007-03-05 CA CA002647087A patent/CA2647087A1/en not_active Abandoned
- 2007-03-05 JP JP2009505732A patent/JP2009534323A/ja active Pending
- 2007-03-05 CN CNA2007800136921A patent/CN101420933A/zh active Pending
- 2007-03-05 CN CN201410705858.8A patent/CN104524542A/zh active Pending
- 2007-03-05 US US12/226,358 patent/US8377876B2/en not_active Expired - Fee Related
- 2007-03-05 MX MX2008013540A patent/MX2008013540A/es active IP Right Grant
- 2007-03-05 BR BRPI0710298-4A patent/BRPI0710298A2/pt not_active IP Right Cessation
- 2007-03-05 EA EA200870451A patent/EA015709B1/ru not_active IP Right Cessation
- 2007-03-05 KR KR1020087027628A patent/KR20090010050A/ko not_active Withdrawn
- 2007-03-05 EP EP07711788.5A patent/EP2007348B1/de not_active Not-in-force
- 2007-03-08 TW TW096108010A patent/TWI429405B/zh not_active IP Right Cessation
- 2007-04-20 AR ARP070101703A patent/AR060555A1/es unknown
-
2008
- 2008-09-12 ZA ZA200807860A patent/ZA200807860B/xx unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0087750A2 (de) * | 1982-02-25 | 1983-09-07 | Kabi Pharmacia GmbH | Glutaminhaltige Aminosäure-Zubereitungen |
| WO1991016067A1 (en) * | 1990-04-23 | 1991-10-31 | Research Corporation Technologies, Inc. | Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition |
| WO1992009277A1 (en) * | 1990-12-03 | 1992-06-11 | Kabi Pharmacia Ab | Nutrient supply |
| US5432160A (en) * | 1993-01-29 | 1995-07-11 | Kyowa Hakko Kohyo Co., Ltd. | Nutrient composition |
| US5561111A (en) * | 1994-12-23 | 1996-10-01 | The University Of Virginia Patent Foundation | Stable glutamine derivatives for oral and intravenous rehydration and nutrition therapy |
| WO2005030242A1 (en) * | 2003-09-26 | 2005-04-07 | University Of Florida Research Foundation, Inc | Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation |
Non-Patent Citations (1)
| Title |
|---|
| LACEY J.M. ET AL.: "The effects of glutamine-supplemented parenteral nutrition in premature infants", JPEN, vol. 20, no. 1, 1996, pages 74-80, XP009083795, pages 74-75, tab. I, II, tab. I * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2608232C2 (ru) * | 2012-01-09 | 2017-01-17 | Н.В. Нютрисиа | Обогащенная глутамином питательная композиция для недоношенных детей |
| RU2619294C2 (ru) * | 2013-01-09 | 2017-05-15 | Н.В. Нютрисиа | Улучшение познавательных способностей недоношенных детей, имеющих низкую массу для своего гестационного возраста |
| WO2020222671A1 (ru) * | 2019-04-29 | 2020-11-05 | Алексей Владимирович ВОРОНОВ | Солевой электролитный раствор для проведения энтеральных инфузий |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0710298A2 (pt) | 2011-08-09 |
| US20090203626A1 (en) | 2009-08-13 |
| EA200870451A1 (ru) | 2009-04-28 |
| AR060555A1 (es) | 2008-06-25 |
| WO2007121807A1 (de) | 2007-11-01 |
| JP2009534323A (ja) | 2009-09-24 |
| US8377876B2 (en) | 2013-02-19 |
| MX2008013540A (es) | 2008-10-31 |
| CN104524542A (zh) | 2015-04-22 |
| CN101420933A (zh) | 2009-04-29 |
| ZA200807860B (en) | 2009-08-26 |
| EP2007348B1 (de) | 2014-12-10 |
| KR20090010050A (ko) | 2009-01-28 |
| TWI429405B (zh) | 2014-03-11 |
| AU2007241469A1 (en) | 2007-11-01 |
| EP2007348A1 (de) | 2008-12-31 |
| CA2647087A1 (en) | 2007-11-01 |
| AU2007241469B2 (en) | 2012-09-20 |
| TW200740380A (en) | 2007-11-01 |
| DE102006018293A1 (de) | 2007-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA015709B1 (ru) | Педиатрический аминокислотный раствор для парентерального питания и его применение | |
| Kenji Imura et al. | Amino acid metabolism in pediatric patients | |
| CN101061860B (zh) | 富含亮氨酸的营养组合物 | |
| ES2263602T3 (es) | Composicion que comprende aminoacidos libres. | |
| JP5574561B2 (ja) | 総合経腸栄養組成物 | |
| JP5315996B2 (ja) | 総合経腸栄養組成物 | |
| JP2007291135A (ja) | 不快を緩和するための医薬組成物 | |
| ES2314485T3 (es) | Composiciones que comprenden acido pantotenico o derivados del mismo y su uso para estimular el apetito. | |
| KR20170104575A (ko) | 신부전 환자를 치료하기 위한 카복실산 혼합물 | |
| US20100137226A1 (en) | Fatigue-reducing agent | |
| US5206220A (en) | Soluble and stable sources of tyrosine, cysteine and glutamine for total parenteral nutrition | |
| US20050064014A1 (en) | Use of cystathionine | |
| Parimi et al. | Glutamine supplementation in the newborn infant | |
| ES2337495T3 (es) | Composiciones que comprenden galato de epigalocatecina e hidrolizado de proteina. | |
| JPS63307822A (ja) | 腎不全用アミノ酸輸液 | |
| JPH0328403B2 (enExample) | ||
| RU2335927C2 (ru) | Обогащенные лейцином питательные композиции | |
| US12370162B1 (en) | Dietary glycine and serine restriction for cancer treatment | |
| Bell et al. | Modular enteral diets: Cost and nutritional value comparisons | |
| KR20010113087A (ko) | 타우린이 첨가된 우유 및 유제품 | |
| JPWO1988008259A1 (ja) | 栄養乳液製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |